COMMUNIQUÉS West-GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
03/06/2024
SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with [...]
Publication relating to transparency notifications
03/06/2024
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of [...]
Publication relative à des notifications de transparence
03/06/2024
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 3 juin 2024, 22:05h CET / 16:05h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la [...]
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
03/06/2024
LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company’s common shares to [...]
PROCEPT BioRobotics to Present at Upcoming 2024 Truist Securities MedTech Conference on June 18, 2024
03/06/2024
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, [...]
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) significantly improved progression-free survival and deepened responses versus two standard therapies for patients with functional high-risk multiple myeloma
03/06/2024
73 percent reduction in risk of disease progression or death seen with cilta-cel in the CARTITUDE-4 study in a subset of patients who had early relapse after initial multiple myeloma therapy 1 BEERSE, BELGIUM, June 03, [...]
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
03/06/2024
The safety and efficacy of FG-3165 will be evaluated in a Phase 1 trial in select solid tumors Plan to begin enrollment in 2H 2024 SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today [...]
Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
03/06/2024
- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during setmelanotide therapy in qualitative interviews - - Separate analysis of patients across MC4R [...]
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
03/06/2024
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70 [...]
HealthEquity Reports First Quarter Ended April 30, 2024 Financial Results
03/06/2024
Highlights of the first quarter include: Revenue of $287.6 million, an increase of 18% compared to $244.4 million in Q1 FY24. Net income of $28.8 million, compared to $4.1 million in Q1 FY24, with non-GAAP net income of [...]
Invivyd to Participate at the Jefferies Global Healthcare Conference
03/06/2024
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management [...]
Celcuity To Participate in Jefferies Global Healthcare Conference
03/06/2024
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the [...]
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
03/06/2024
PALO ALTO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its [...]
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
03/06/2024
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited confirmed [...]
CloudMD Announces Filing and Mailing of the Management Information Circular in Connection with the Proposed Go-Private Transaction with CPS Capital
03/06/2024
Your vote is important no matter how many shares you hold. The Board of Directors of CloudMD unanimously recommends that Securityholders vote IN FAVOUR of the Arrangement Resolution. Questions or requests for voting [...]
BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients
03/06/2024
TCX-101 Clinical Program : TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse First patient to be [...]
Oxford Treatment Center Launches The Rally Point: Valkyrie Program, a Specialty Program for Female Veterans
03/06/2024
OXFORD, Miss., June 03, 2024 (GLOBE NEWSWIRE) -- Oxford Treatment Center has launched a new specialized treatment program specifically tailored for female Veterans. The Rally Point: Valkyrie Program draws inspiration [...]
Public Hearings on Protecting and Improving Local Hospitals: Community members invited to give input
03/06/2024
TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- In response to more than 1,200 closures of emergency departments and other local hospital services over the last year, the Ontario Health Coalition (OHC) is holding public [...]
Late-breaking results from PALOMA-2 study of subcutaneous RYBREVANT®▼ (amivantamab) in combination with lazertinib show clinically meaningful antitumour response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
03/06/2024
Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data 1 BEERSE, BELGIUM, June 03, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag [...]

Pages